5 recruiting, 3 active not recruiting, 2 completed, 1 not yet recruiting. 6 Phase 1, 6 Phase 2, 1 Not applicable.
Follow High Grade B-Cell Lymphoma: new trials by email Literature Review of High Grade B-Cell Lymphoma trials Research Report on High Grade B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Immunotherapy in Lymphoma CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate - Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma | Recruiting | Sung-Soo Park | 72 | 2024-06-26 | 2025-01-28 | |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2024-06-13 | 2026-07-07 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Lenalidomide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-05-20 | 2026-10-26 |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU Long-term Follow-Up - Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Recruiting | Miltenyi Biomedicine GmbH | 150 | 2024-05-15 | 2026-08-05 | |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2025-10-20 |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 33 | 2023-01-26 | 2026-06-22 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma Molecular Nanotechnology - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Not applicable | Active not recruiting | Ohio State University Comprehensive Cancer Center | 73 | 2018-09-26 | 2026-08-06 |
| Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas Venetoclax, Rituximab, Etoposide - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 | Completed | Weill Medical College of Cornell University | 31 | 2017-02-06 | 2022-08-24 |
| Treatment for Advanced B-Cell Lymphoma Rituximab, IT Cytarabine - Diffuse Large Cell Lymphoma, Burkitt's Lymphoma | Phase 2 | Completed | New York Medical College | 45 | 2013-01-01 | 2022-10-25 |
Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Non-Hodgkin (3) · Burkitt Lymphoma (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Disease Progression (1) · Lymphoma, Follicular (1) · Recurrence (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Lymphoma (10) · Lymphoma, B-Cell (10) · Lymphoma, Non-Hodgkin (9) · DNA Virus Infections (2) · Disease Attributes (2) · Epstein-Barr Virus Infections (2) · Herpesviridae Infections (2) · Infections (2)
Cyclophosphamide (5) · Magnetic Resonance Spectroscopy (5) · Doxorubicin (4) · Prednisone (4) · Rituximab (4) · Specimen Handling (4) · Vincristine (3) · polatuzumab vedotin (3) · Disulfides (2) · Etoposide (2) · Immunoglobulins (2) · Lenalidomide (2) · axicabtagene ciloleucel (2) · deltacortene (2) · prednylidene (2)
Jonsson Comprehensive Cancer Center (2) · University of Washington (2) · Miltenyi Biomedicine GmbH (1) · National Cancer Institute (NCI) (1) · New York Medical College (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1) · Sung-Soo Park (1) · Weill Medical College of Cornell University (1)
United States (11) · South Korea (1)
Ajay Gopal (1) · Beth Christian, MD (1) · Jennifer E Amengual (1) · Jeremy S. Abramson, M.D. (1) · John M Timmerman, MD (1) · John P. Leonard, M.D. (1) · Joseph M Tuscano (1) · Mitchell S Cairo, MD (1) · Remi Kaleta, MD (1) · Sarah Rutherford, M.D. (1) · Stanton Goldman, MD (1) · Stephen D. Smith (1) · Stephen E Spurgeon (1) · Sven De Vos (1)
U10CA180888 (1), UM1CA186717 (1)